Obesity is a growing global problem, with over 1 billion people worldwide considered obese. As a result, the demand for drugs to address this condition is higher than ever. Novo Nordisk and Eli Lilly are two companies that have seen a surge in market value due to their innovative weight-loss medications.
Join hosts Alice Fulwood, Mike Bird, and Tom Lee-Devlin as they unpack how these drugs are not only benefiting drug companies financially but also reshaping the economy. They will be joined by experts such as The Economist’s Georgia Banjo, pharmaceuticals analyst Michael Nedelcovych, and John Cawley, a professor at Cornell University, who will provide expert insights on the topic.
The Economist Podcast covers a wide range of topics from global politics and business to science and technology. Subscribe now to stay informed and up-to-date on what matters most in the world. To get access to Economist Podcasts+, visit the FAQs page or watch a video on how to link your account.
For those interested in podcast transcripts, simply reach out to [email protected] The Economist is dedicated to improving accessibility and is exploring new ways to expand the podcast-transcript offering. Listen to the podcast on Apple Podcasts or Spotify to stay informed on the latest global trends and discussions.
